{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:00:52Z","timestamp":1781632852002,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303408"],"award-info":[{"award-number":["82303408"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M763536"],"award-info":[{"award-number":["2024M763536"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer is a highly heterogeneous malignancy, with distinct subtypes displaying unique molecular and metabolic profiles. This study identifies a compensatory shift in \u03b1-ketoglutarate (\u03b1-KG) metabolism in prostate cancer, where the tumor relies on IDH1 to incorporate citrate into the TCA cycle. IDH1 inhibition, leads to lower \u03b1-KG levels. Since \u03b1-KG is required for HIF-1\u03b1 hydroxylation, IDH1 inhibition stabilizes HIF-1\u03b1, which subsequently upregulates c-Fos. C-Fos enhances GLUD1 transcription, promoting the conversion of glutamate to \u03b1-KG as a compensatory mechanism. Additionally, c-Fos upregulates downstream effectors, including FOXC1 and SOX2, driving neuroendocrine differentiation in prostate cancer. Targeting \u03b1-KG-metabolizing enzymes, such as IDH1 or GLUD1, presents promising therapeutic strategies for prostate cancer subtypes by inhibiting tumor proliferation and inducing oxidative stress, thus sensitizing tumors to ferroptosis. Overall, these findings uncover a metabolic adaptation in response to IDH1 inhibition and highlight the pivotal role of c-Fos in mediating this compensatory pathway, offering new insights into potential metabolic targets for prostate cancer treatment and ferroptosis-based therapies.<\/jats:p>","DOI":"10.1038\/s41419-026-08918-4","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:42:26Z","timestamp":1780299746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["c-Fos-driven metabolic switch of \u03b1-ketoglutarate orchestrates progression in prostate cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Liyan","family":"Ao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1520-9455","authenticated-orcid":false,"given":"Jin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0588-7408","authenticated-orcid":false,"given":"Qilong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobin","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4111-5360","authenticated-orcid":false,"given":"Weimin","family":"Ci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouhuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6908-6768","authenticated-orcid":false,"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9705-0281","authenticated-orcid":false,"given":"Shaoxi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"8918_CR1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/nrurol.2016.80","volume":"13","author":"C Thoma","year":"2016","unstructured":"Thoma C. Prostate cancer: towards effective combination of ADT and immunotherapy. Nat Rev Urol. 2016;13:300. https:\/\/doi.org\/10.1038\/nrurol.2016.80.","journal-title":"Nat Rev Urol"},{"key":"8918_CR2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21:1067\u201396. https:\/\/doi.org\/10.6004\/jnccn.2023.0050.","journal-title":"J Natl Compr Canc Netw"},{"key":"8918_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","volume":"81","author":"Q Cheng","year":"2022","unstructured":"Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K, et al. Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy. Eur Urol. 2022;81:446\u201355. https:\/\/doi.org\/10.1016\/j.eururo.2021.12.039.","journal-title":"Eur Urol"},{"key":"8918_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/2159-8290.CD-23-0754","volume":"14","author":"GM Franceschini","year":"2024","unstructured":"Franceschini GM, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku S-Y, et al. Noninvasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation. Cancer Discov. 2024;14:424\u201345. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0754.","journal-title":"Cancer Discov"},{"key":"8918_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semcancer.2022.05.007","volume":"86","author":"S Liu","year":"2022","unstructured":"Liu S, Alabi BR, Yin Q, Stoyanova T. Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Semin Cancer Biol. 2022;86:57\u201368. https:\/\/doi.org\/10.1016\/j.semcancer.2022.05.007.","journal-title":"Semin Cancer Biol"},{"key":"8918_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang Y, Ci X, Choi SYC, Crea F, Lin D, et al. Molecular events in neuroendocrine prostate cancer development. Nat Rev Urol. 2021;18:581\u201396. https:\/\/doi.org\/10.1038\/s41585-021-00490-0.","journal-title":"Nat Rev Urol"},{"key":"8918_CR7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/1078-0432.CCR-24-2061","volume":"31","author":"MC Haffner","year":"2025","unstructured":"Haffner MC, Morris MJ, Ding C-KC, Sayar E, Mehra R, Robinson B, et al. Framework for the pathology workup of metastatic castration-resistant prostate cancer biopsies. Clin Cancer Res. 2025;31:466\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2061.","journal-title":"Clin Cancer Res"},{"key":"8918_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021;23:15. https:\/\/doi.org\/10.1007\/s11912-020-01003-9.","journal-title":"Curr Oncol Rep"},{"key":"8918_CR9","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/s41418-022-00960-x","volume":"29","author":"Y Peng","year":"2022","unstructured":"Peng Y, Liu J, Wang Z, Cui C, Zhang T, Zhang S, et al. Prostate-specific oncogene OTUD6A promotes prostatic tumorigenesis via deubiquitinating and stabilizing c-Myc. Cell Death Differ. 2022;29:1730\u201343. https:\/\/doi.org\/10.1038\/s41418-022-00960-x.","journal-title":"Cell Death Differ"},{"key":"8918_CR10","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1172\/JCI127961","volume":"129","author":"A Berger","year":"2019","unstructured":"Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, et al. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J Clin Invest. 2019;129:3924\u201340. https:\/\/doi.org\/10.1172\/JCI127961.","journal-title":"J Clin Invest"},{"key":"8918_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","volume":"17","author":"\u00c1 Quintanal-Villalonga","year":"2020","unstructured":"Quintanal-Villalonga \u00c1, Chan JM, Yu HA, Pe\u2019er D, Sawyers CL, Sen T, et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020;17:360\u201371. https:\/\/doi.org\/10.1038\/s41571-020-0340-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"8918_CR12","doi-asserted-by":"publisher","DOI":"10.34133\/research.0791","volume":"8","author":"M Cai","year":"2025","unstructured":"Cai M, Zheng F, Ren Y-Z, Zhen C, Fu D, Song X-L, et al. New insights into potential therapeutic targets for neuroendocrine prostate cancer: from bench to clinic. Research. 2025;8:0791. https:\/\/doi.org\/10.34133\/research.0791.","journal-title":"Research"},{"key":"8918_CR13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.7150\/thno.92336","volume":"14","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhao F, Lin Y, Liu M, Zhou H, Cui F, et al. Integrated analysis of single-cell and bulk transcriptomics develops a robust neuroendocrine cell-intrinsic signature to predict prostate cancer progression. Theranostics. 2024;14:1065\u201380. https:\/\/doi.org\/10.7150\/thno.92336.","journal-title":"Theranostics"},{"key":"8918_CR14","doi-asserted-by":"publisher","unstructured":"Maylin ZR, Smith C, Classen A, Asim M, Pandha H, Wang Y. Therapeutic exploitation of neuroendocrine transdifferentiation drivers in prostate cancer. Cells. 2024;13. https:\/\/doi.org\/10.3390\/cells13231999.","DOI":"10.3390\/cells13231999"},{"key":"8918_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2021","unstructured":"Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2021;21:141\u201362. https:\/\/doi.org\/10.1038\/s41573-021-00339-6.","journal-title":"Nat Rev Drug Discov"},{"key":"8918_CR16","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.cmet.2023.07.006","volume":"35","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Yu T-J, Xu Y, Ding R, Wang Y-P, Jiang Y-Z, et al. Emerging therapies in cancer metabolism. Cell Metab. 2023;35:1283\u2013303. https:\/\/doi.org\/10.1016\/j.cmet.2023.07.006.","journal-title":"Cell Metab"},{"key":"8918_CR17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.mam.2012.11.007","volume":"34","author":"MC Franz","year":"2013","unstructured":"Franz MC, Anderle P, B\u00fcrzle M, Suzuki Y, Freeman MR, Hediger MA, et al. Zinc transporters in prostate cancer. Mol Asp Med. 2013;34:735\u201341. https:\/\/doi.org\/10.1016\/j.mam.2012.11.007.","journal-title":"Mol Asp Med"},{"key":"8918_CR18","doi-asserted-by":"publisher","unstructured":"Acevedo S, Segovia MF, de la Fuente-Ortega E. Emerging perspectives in zinc transporter research in prostate cancer: an updated review. Nutrients. 2024;16. https:\/\/doi.org\/10.3390\/nu16132026","DOI":"10.3390\/nu16132026"},{"key":"8918_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-4-32","volume":"4","author":"RB Franklin","year":"2005","unstructured":"Franklin RB, Feng P, Milon B, Desouki MM, Singh KK, Kajdacsy-Balla A, et al. hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer. 2005;4:32.","journal-title":"Mol Cancer"},{"key":"8918_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/pros.24883","volume":"85","author":"Y Li","year":"2025","unstructured":"Li Y, Wu Z, Ma J, Liu X, Zhang C, Ma J, et al. Zinc attenuates prostate hyperplasia and inflammatory injury in obese rats by regulating zinc homeostasis and inhibiting the JAK1\/STAT3 pathway. Prostate. 2025;85:767\u201376. https:\/\/doi.org\/10.1002\/pros.24883.","journal-title":"Prostate"},{"key":"8918_CR21","first-page":"69","volume":"19","author":"A Fallah","year":"2018","unstructured":"Fallah A, Mohammad-Hasani A, Colagar AH. Zinc is an essential element for male fertility: a review of Zn roles in men\u2019s health, germination, sperm quality, and fertilization. J Reprod Infertil. 2018;19:69\u201381.","journal-title":"J Reprod Infertil"},{"key":"8918_CR22","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/1541-7786.MCR-19-0020","volume":"17","author":"K Gonthier","year":"2019","unstructured":"Gonthier K, Poluri RTK, Weidmann C, Tadros M, Audet-Walsh \u00c9. Reprogramming of isocitrate dehydrogenases expression and activity by the androgen receptor in prostate cancer. Mol Cancer Res. 2019;17:1699\u2013709. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0020.","journal-title":"Mol Cancer Res"},{"key":"8918_CR23","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1002\/1878-0261.13441","volume":"17","author":"K Gonthier","year":"2023","unstructured":"Gonthier K, Weidmann C, Berthiaume L, Jobin C, Lacouture A, Lafront C, et al. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer. Mol Oncol. 2023;17:2109\u201325. https:\/\/doi.org\/10.1002\/1878-0261.13441.","journal-title":"Mol Oncol"},{"key":"8918_CR24","doi-asserted-by":"publisher","unstructured":"Xu L, Yin Y, Li Y, Chen X, Chang Y, Zhang H et al. A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proc Natl Acad Sci USA 2021;118. https:\/\/doi.org\/10.1073\/pnas.2012748118.","DOI":"10.1073\/pnas.2012748118"},{"key":"8918_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202408996","volume":"21","author":"X Chen","year":"2025","unstructured":"Chen X, Kadier M, Shi M, Li K, Chen H, Xia Y, et al. Targeting melatonin to mitochondria mitigates castration-resistant prostate cancer by inducing pyroptosis. Small. 2025;21:e2408996. https:\/\/doi.org\/10.1002\/smll.202408996.","journal-title":"Small"},{"key":"8918_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03573-6","volume":"9","author":"L Latonen","year":"2018","unstructured":"Latonen L, Afyounian E, Jylh\u00e4 A, N\u00e4ttinen J, Aapola U, Annala M, et al. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun. 2018;9:1176. https:\/\/doi.org\/10.1038\/s41467-018-03573-6.","journal-title":"Nat Commun"},{"key":"8918_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf8822","volume":"381","author":"F Huang","year":"2023","unstructured":"Huang F, Luo X, Ou Y, Gao Z, Tang Q, Chu Z, et al. Control of histone demethylation by nuclear-localized \u03b1-ketoglutarate dehydrogenase. Science. 2023;381:eadf8822. https:\/\/doi.org\/10.1126\/science.adf8822.","journal-title":"Science"},{"key":"8918_CR28","doi-asserted-by":"publisher","unstructured":"Wang X, Liu R, Qu X, Yu H, Chu H, Zhang Y et al. \u03b1-Ketoglutarate-activated NF-\u03baB signaling promotes compensatory glucose uptake and brain tumor development. Mol Cell. 2019;76. https:\/\/doi.org\/10.1016\/j.molcel.2019.07.007.","DOI":"10.1016\/j.molcel.2019.07.007"},{"key":"8918_CR29","doi-asserted-by":"crossref","unstructured":"Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer. 2006;5:17.","DOI":"10.1186\/1476-4598-5-17"},{"key":"8918_CR30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41586-020-2475-6","volume":"585","author":"I Mart\u00ednez-Reyes","year":"2020","unstructured":"Mart\u00ednez-Reyes I, Cardona LR, Kong H, Vasan K, McElroy GS, Werner M, et al. Mitochondrial ubiquinol oxidation is necessary for tumour growth. Nature. 2020;585:288\u201392. https:\/\/doi.org\/10.1038\/s41586-020-2475-6.","journal-title":"Nature"},{"key":"8918_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41392-020-00326-0","volume":"5","author":"H-Q Ju","year":"2020","unstructured":"Ju H-Q, Lin J-F, Tian T, Xie D, Xu R-H. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Target Ther. 2020;5:231. https:\/\/doi.org\/10.1038\/s41392-020-00326-0.","journal-title":"Signal Transduct Target Ther"},{"key":"8918_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121110","volume":"277","author":"B Niu","year":"2021","unstructured":"Niu B, Liao K, Zhou Y, Wen T, Quan G, Pan X, et al. Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials. 2021;277:121110. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121110.","journal-title":"Biomaterials"},{"key":"8918_CR33","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25:424\u201342. https:\/\/doi.org\/10.1038\/s41580-024-00703-5.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8918_CR34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1158\/2159-8290.CD-21-0218","volume":"13","author":"D Thomas","year":"2023","unstructured":"Thomas D, Wu M, Nakauchi Y, Zheng M, Thompson-Peach CAL, Lim K, et al. Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability. Cancer Discov. 2023;13:496\u2013515. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0218.","journal-title":"Cancer Discov"},{"key":"8918_CR35","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.3171\/2014.9.FOCUS14505","volume":"37","author":"S Agnihotri","year":"2014","unstructured":"Agnihotri S, Aldape KD, Zadeh G. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. Neurosurg Focus. 2014;37:E13. https:\/\/doi.org\/10.3171\/2014.9.FOCUS14505.","journal-title":"Neurosurg Focus"},{"key":"8918_CR36","doi-asserted-by":"publisher","unstructured":"Kao S-H, Wu K-J, Lee W-H. Hypoxia, epithelial-mesenchymal transition, and TET-mediated epigenetic changes. J Clin Med. 2016;5. https:\/\/doi.org\/10.3390\/jcm5020024.","DOI":"10.3390\/jcm5020024"},{"key":"8918_CR37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.biopha.2017.02.083","volume":"89","author":"H Semukunzi","year":"2017","unstructured":"Semukunzi H, Roy D, Li H, Khan GJ, Lyu X, Yuan S, et al. IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1\u03b1. Biomed Pharmacother. 2017;89:805\u201311. https:\/\/doi.org\/10.1016\/j.biopha.2017.02.083.","journal-title":"Biomed Pharmacother"},{"key":"8918_CR38","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1038\/s41418-018-0265-6","volume":"26","author":"Y-A Wen","year":"2019","unstructured":"Wen Y-A, Xiong X, Scott T, Li AT, Wang C, Weiss HL, et al. The mitochondrial retrograde signaling regulates Wnt signaling to promote tumorigenesis in colon cancer. Cell Death Differ. 2019;26:1955\u201369. https:\/\/doi.org\/10.1038\/s41418-018-0265-6.","journal-title":"Cell Death Differ"},{"key":"8918_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13046-018-0894-0","volume":"37","author":"S Cao","year":"2018","unstructured":"Cao S, Wang Z, Gao X, He W, Cai Y, Chen H, et al. FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC. J Exp Clin Cancer Res. 2018;37:220. https:\/\/doi.org\/10.1186\/s13046-018-0894-0.","journal-title":"J Exp Clin Cancer Res"},{"key":"8918_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26901-9","volume":"12","author":"N Singh","year":"2021","unstructured":"Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, et al. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021;12:7349. https:\/\/doi.org\/10.1038\/s41467-021-26901-9.","journal-title":"Nat Commun"},{"key":"8918_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40779-024-00526-7","volume":"11","author":"D-C Feng","year":"2024","unstructured":"Feng D-C, Zhu W-Z, Wang J, Li D-X, Shi X, Xiong Q, et al. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy. Mil Med Res. 2024;11:21. https:\/\/doi.org\/10.1186\/s40779-024-00526-7.","journal-title":"Mil Med Res"},{"key":"8918_CR42","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.eururo.2021.03.009","volume":"80","author":"S Wilkinson","year":"2021","unstructured":"Wilkinson S, Ye H, Karzai F, Harmon SA, Terrigino NT, VanderWeele DJ, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. 2021;80:746\u201357. https:\/\/doi.org\/10.1016\/j.eururo.2021.03.009.","journal-title":"Eur Urol"},{"key":"8918_CR43","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1006\/geno.1993.1152","volume":"16","author":"TM Michaelidis","year":"1993","unstructured":"Michaelidis TM, Tzimagiorgis G, Moschonas NK, Papamatheakis J. The human glutamate dehydrogenase gene family: gene organization and structural characterization. Genomics. 1993;16:150\u201360.","journal-title":"Genomics"},{"key":"8918_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jncc.2025.11.001","volume":"6","author":"V Keo","year":"2025","unstructured":"Keo V, Lu X, Zhao JC, Yu J. Genetic and epigenetic mechanisms underlying treatment-induced neuroendocrine prostate cancer. J Natl Cancer Cent. 2025;6:88\u201397. https:\/\/doi.org\/10.1016\/j.jncc.2025.11.001.","journal-title":"J Natl Cancer Cent"},{"key":"8918_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.mocell.2025.100193","volume":"48","author":"J Lee","year":"2025","unstructured":"Lee J, Lee Y. The role of transcription factors in prostate cancer progression. Mol Cells. 2025;48:100193. https:\/\/doi.org\/10.1016\/j.mocell.2025.100193.","journal-title":"Mol Cells"},{"key":"8918_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22139-7","volume":"12","author":"SC Baca","year":"2021","unstructured":"Baca SC, Takeda DY, Seo J-H, Hwang J, Ku SY, Arafeh R, et al. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021;12:1979. https:\/\/doi.org\/10.1038\/s41467-021-22139-7.","journal-title":"Nat Commun"},{"key":"8918_CR47","doi-asserted-by":"publisher","unstructured":"Han M, Li F, Zhang Y, Dai P, He J, Li Y et al. FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer. Cancer Cell. 2022;40. https:\/\/doi.org\/10.1016\/j.ccell.2022.10.011.","DOI":"10.1016\/j.ccell.2022.10.011"},{"key":"8918_CR48","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/j.1464-410X.2009.08351.x","volume":"103","author":"L van der Heul-Nieuwenhuijsen","year":"2009","unstructured":"van der Heul-Nieuwenhuijsen L, Dits NF, Jenster G. Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int. 2009;103:1574\u201380. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08351.x.","journal-title":"BJU Int"},{"key":"8918_CR49","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41374-019-0343-5","volume":"100","author":"H Li","year":"2019","unstructured":"Li H, Wang L, Li Z, Geng X, Li M, Tang Q, et al. SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer. Lab Invest. 2019;100:570\u201382. https:\/\/doi.org\/10.1038\/s41374-019-0343-5.","journal-title":"Lab Invest"},{"key":"8918_CR50","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41388-020-01526-2","volume":"40","author":"O-J Kwon","year":"2020","unstructured":"Kwon O-J, Zhang L, Jia D, Xin L. Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1+ prostate luminal cells. Oncogene. 2020;40:203\u201314. https:\/\/doi.org\/10.1038\/s41388-020-01526-2.","journal-title":"Oncogene"},{"key":"8918_CR51","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","volume":"403","author":"CC Parker","year":"2024","unstructured":"Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, et al. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet. 2024;403:2416\u201325. https:\/\/doi.org\/10.1016\/S0140-6736(24)00549-X.","journal-title":"Lancet"},{"key":"8918_CR52","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41420-024-02031-1","volume":"10","author":"D Zheng","year":"2024","unstructured":"Zheng D, Zhang Y, Yang S, Su N, Bakhoum M, Zhang G, et al. Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1\/EZH2-mediated downregulation of REST. Cell Death Discov. 2024;10:246. https:\/\/doi.org\/10.1038\/s41420-024-02031-1.","journal-title":"Cell Death Discov"},{"key":"8918_CR53","doi-asserted-by":"publisher","unstructured":"Patel GK, Chugh N, Tripathi M. Neuroendocrine differentiation of prostate cancer-an intriguing example of tumor evolution at play. Cancers. 2019;11. https:\/\/doi.org\/10.3390\/cancers11101405.","DOI":"10.3390\/cancers11101405"},{"key":"8918_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9:55. https:\/\/doi.org\/10.1038\/s41392-024-01769-5.","journal-title":"Signal Transduct Target Ther"},{"key":"8918_CR55","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani A, Hsu E-C, Aslan M, Rice MA, Nguyen HM, Brooks JD, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 2021;81:1583\u201394. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3477.","journal-title":"Cancer Res"},{"key":"8918_CR56","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41585-024-00869-9","volume":"21","author":"PHA Cao","year":"2024","unstructured":"Cao PHA, Dominic A, Lujan FE, Senthilkumar S, Bhattacharya PK, Frigo DE, et al. Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers. Nat Rev Urol. 2024;21:615\u201337. https:\/\/doi.org\/10.1038\/s41585-024-00869-9.","journal-title":"Nat Rev Urol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08918-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08918-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08918-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:46:00Z","timestamp":1781631960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08918-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8918"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08918-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The collection of tumor tissue samples was approved by the Ethics Committee of the Chinese PLA General Hospital with registration number and all patients gave informed consent (S2024-778-01). All methods were performed in strict accordance with the relevant guidelines and regulations. All animal experiments described in this study were performed in strict accordance with national and institutional guidelines for the care and use of laboratory animals. The study protocol, including animal breeding, maintenance, all experimental procedures (such as monitoring or tumor collection), and the humane endpoint criteria, was reviewed and formally approved by Institutional Animal Use and Care Committee of our institution and granted approval with AP# GPT-BJAP001-E2505140034.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"574"}}